Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based study
- 7 December 2007
- journal article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 158 (2) , 351-359
- https://doi.org/10.1111/j.1365-2133.2007.08354.x
Abstract
Background Health utilities are used to express relevant trade-offs for resource allocation. The absence of valid and generalizable utilities for atopic eczema (AE) and psoriasis limits the validity of previous cost-utility analyses. Objectives (i) To assess health utilities of standardized scenarios of controlled and uncontrolled AE and psoriasis in participants from the general population and in patients using the time trade-off (TTO) method; (ii) to test the association of the utilities obtained with demographic and patient characteristics; and (iii) to compare these utilities with other health economic outcomes [utilities assessed on visual analogue scale (VAS), willingness to pay (WTP)]. Methods A single-centre study conducted in 2006 at the Department of Dermatology, Dresden, Germany. Standardized interactive computer-assisted interviews in a random sample from the general population (n = 139), and patients with AE (n = 58) and psoriasis (n = 62). Information on health states included characteristic clinical pictures and a short text explaining aetiology, signs, symptoms and quality of life impact. Results In participants from the general population median utilities (TTO) of controlled and uncontrolled AE were 0·97 and 0·64, respectively. For psoriasis the corresponding utilities were 0·93 and 0·56. Utilities were independent of sex and socioeconomic position, and tended to be lower in patients with psoriasis. Correlations between TTO, VAS and WTP responses were weak. Conclusions To avoid uncontrolled psoriasis or eczema participants chose an approximately 40% shorter life expectancy. This indicates that severe chronic inflammatory skin diseases may be considered as severe as angina pectoris, chronic anxiety, rheumatoid arthritis, multiple sclerosis or regional oesophageal cancer. The different economic outcomes assessed are not interchangeable.Keywords
This publication has 32 references indexed in Scilit:
- Etanercept and efalizumab for the treatment of psoriasis: a systematic reviewHealth Technology Assessment, 2006
- Work Limitations and Productivity Loss Are Associated with Health-Related Quality of Life but Not with Clinical Severity in Patients with PsoriasisDermatology, 2006
- A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczemaBritish Journal of Dermatology, 2006
- Epidemiology of PsoriasisCurrent Drug Targets - Inflammation & Allergy, 2004
- The cost of atopic dermatitis in the Netherlands: an international comparisonBritish Journal of Dermatology, 2002
- Epidemiology of atopic dermatitisClinical and Experimental Dermatology, 2000
- Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczemaBritish Journal of Dermatology, 1999
- Psoriasis causes as much disability as other major medical diseasesJournal of the American Academy of Dermatology, 1999
- Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical useClinical and Experimental Dermatology, 1994
- Utilities and Quality-Adjusted Life YearsInternational Journal of Technology Assessment in Health Care, 1989